Literature DB >> 31442594

CD38brightCD8+ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells.

Pooja Khandelwal1, Vijaya Chaturvedi2, Erika Owsley2, Adam Lane2, Daria Heyenbruch2, Carolyn M Lutzko3, Thomas Leemhuis2, Michael S Grimley2, Adam S Nelson2, Stella M Davies2, Michael B Jordan4, Rebecca A Marsh2.   

Abstract

We have previously reported that a peripheral blood absolute CD38brightCD8+ effector memory T cell (TEM) population expansion of >35 cells/µL predicts the development of acute graft-versus-host disease (GVHD). We hypothesized that these T cells are activated, proliferating, and cytotoxic trafficking cells that are not a response to viral reactivation and may be involved in acute GVHD. We characterized peripheral blood T cell populations at the time of maximum CD38brightCD8+ TEM expansion in patients from our originally reported pediatric allogeneic hematopoietic cell transplantation recipient cohort. Samples were incubated with fluorochrome-conjugated antibodies directed against CD3, CD8, CD38, HLA-DR (T cell activation), Ki-67 (T cell proliferation), granzyme B (marker of cytotoxic T cells), CLA (skin trafficking), CCR5 (visceral trafficking), and CXCR6 (liver trafficking). We also incubated samples with Epstein-Barr virus (EBV) and cytomegalovirus (CMV) peptide pools and measured IFN-γ production by flow cytometry and performed EBV and CMV tetramer staining. Higher median proportions of cell expression of HLA-DR, Ki-67, granzyme B, CLA, CCR5, and CXCR6 were observed for CD38brightCD8+ T cells compared with CD38nonbrightCD8+ T cells in patients with acute GVHD (P < .05) but not in patients without acute GVHD (P not significant). No IFN-γ production was observed after incubation with CMV and EBV peptide pools. EBV-specific tetramer populations of 6.85% and 3.17% were detected in 2 patients with acute GVHD, whereas a CMV-specific tetramer population of 3.77% was detected in 1 patient with acute GVHD. No EBV- or CMV-specific tetramer populations were detected in any patient without acute GVHD. We conclude that CD38brightCD8+ T cells associated with the development of acute GVHD are activated, proliferating, and cytotoxic trafficking cells that do not appear to respond to CMV or EBV reactivation. Further studies are needed to determine whether these cells are directly involved in acute GVHD pathogenesis.
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute graft-versus-host disease; CD38; CD38(bright)CD8(+) T cells; Graft-versus-host disease

Year:  2019        PMID: 31442594     DOI: 10.1016/j.bbmt.2019.08.008

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  6 in total

1.  Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.

Authors:  Sam R Adhikary; Peter Cuthbertson; Leigh Nicholson; Katrina M Bird; Chloe Sligar; Min Hu; Philip J O'Connell; Ronald Sluyter; Stephen I Alexander; Debbie Watson
Journal:  Immunology       Date:  2021-06-13       Impact factor: 7.215

2.  Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.

Authors:  Benjamin Watkins; Muna Qayed; Courtney McCracken; Brandi Bratrude; Kayla Betz; Yvonne Suessmuth; Alison Yu; Shauna Sinclair; Scott Furlan; Steven Bosinger; Victor Tkachev; James Rhodes; Audrey Grizzle Tumlin; Alexandria Narayan; Kayla Cribbin; Scott Gillespie; Ted A Gooley; Marcelo C Pasquini; Kyle Hebert; Urvi Kapoor; Andre Rogatko; Mourad Tighiouart; Sungjin Kim; Catherine Bresee; Sung W Choi; Jeffrey Davis; Christine Duncan; Roger Giller; Michael Grimley; Andrew C Harris; David Jacobsohn; Nahal Lalefar; Maxim Norkin; Nosha Farhadfar; Michael A Pulsipher; Shalini Shenoy; Aleksandra Petrovic; Kirk R Schultz; Gregory A Yanik; Edmund K Waller; John E Levine; James L Ferrara; Bruce R Blazar; Amelia Langston; John T Horan; Leslie S Kean
Journal:  J Clin Oncol       Date:  2021-01-15       Impact factor: 50.717

3.  A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease.

Authors:  Carina A Bäuerlein; Musga Qureischi; Zeinab Mokhtari; Paula Tabares; Christian Brede; Ana-Laura Jordán Garrote; Simone S Riedel; Martin Chopra; Simone Reu; Anja Mottok; Estibaliz Arellano-Viera; Carolin Graf; Miriam Kurzwart; Katharina Schmiedgen; Hermann Einsele; Matthias Wölfl; Paul-Gerhardt Schlegel; Andreas Beilhack
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

4.  Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.

Authors:  Yang Gao; Wei Shan; Tianning Gu; Jie Zhang; Yibo Wu; Xiaoqing Li; Xiangjun Zeng; Hongyu Zhou; Zhi Chen; Haowen Xiao
Journal:  Front Immunol       Date:  2021-12-20       Impact factor: 7.561

5.  Distinguishing immune activation and inflammatory signatures of multisystem inflammatory syndrome in children (MIS-C) versus hemophagocytic lymphohistiocytosis (HLH).

Authors:  Deepak Kumar; Christina A Rostad; Preeti Jaggi; D Sofia Villacis Nunez; Chengyu Prince; Austin Lu; Laila Hussaini; Thinh H Nguyen; Sakshi Malik; Lori A Ponder; Sreekala P V Shenoy; Evan J Anderson; Michael Briones; Ignacio Sanz; Sampath Prahalad; Shanmuganathan Chandrakasan
Journal:  J Allergy Clin Immunol       Date:  2022-03-15       Impact factor: 14.290

Review 6.  Insights into mechanisms of graft-versus-host disease through humanised mouse models.

Authors:  Amal Elhage; Chloe Sligar; Debbie Watson; Ronald Sluyter; Peter Cuthbertson
Journal:  Biosci Rep       Date:  2022-09-30       Impact factor: 3.976

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.